Literature DB >> 14741152

Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin.

Eric Houpt1, Lisa Barroso, Lauren Lockhart, Rhonda Wright, Carole Cramer, David Lyerly, William A Petri.   

Abstract

Prevention of intestinal infection by Entamoeba histolytica would block both invasive disease and parasite transmission. The amebic Gal/GalNAc lectin mediates parasite adherence to the colonic surface and fecal anti-lectin IgA is associated with protection from intestinal reinfection in children. We tested if vaccination with the E. histolytica Gal/GalNAc lectin could prevent cecal infection in a C3H mouse model of amebic colitis. Two trials using native lectin purified from the parasite and two trials using a 64 kDa recombinant fragment ("LecA") were performed with a combined intranasal and intraperitoneal immunization regimen using cholera toxin and Freund's adjuvants, respectively. Two weeks after immunization mice were challenged intracecally with trophozoites, and 4-12 weeks after challenge mice were sacrificed for histopathologic evaluation of infection. Vaccination prevented intestinal infection with efficacies of 84 and 100% in the two native lectin trials and 91 and 34% in the two LecA trials. Mice with detectable pre-challenge fecal anti-lectin IgA responses were significantly more resistant to infection than mice without fecal anti-lectin IgA responses. These results show for the first time that immunization with the Gal/GalNAc lectin can prevent intestinal amebiasis in mice and suggest a protective role for fecal anti-lectin IgA in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14741152     DOI: 10.1016/j.vaccine.2003.09.003

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.

Authors:  Mayuresh M Abhyankar; Zannatun Noor; Mark A Tomai; James Elvecrog; Christopher B Fox; William A Petri
Journal:  Vaccine       Date:  2017-01-12       Impact factor: 3.641

2.  Evaluation of Entamoeba histolytica antigen and antibody point-of-care tests for the rapid diagnosis of amebiasis.

Authors:  Megan Leo; Rashidul Haque; Mamun Kabir; Shantanu Roy; Rita Marie Lahlou; Dinesh Mondal; Egbert Tannich; William A Petri
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

3.  Stable expression of Gal/GalNAc lectin of Entamoeba histolytica in transgenic chloroplasts and immunogenicity in mice towards vaccine development for amoebiasis.

Authors:  Seethamahalakshmi Chebolu; Henry Daniell
Journal:  Plant Biotechnol J       Date:  2007-03       Impact factor: 9.803

4.  Mucosal immunity to asymptomatic Entamoeba histolytica and Entamoeba dispar infection is associated with a peak intestinal anti-lectin immunoglobulin A antibody response.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Tyson Rogers; Selvan Reddy; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

5.  CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine.

Authors:  Xiaoti Guo; Lisa Barroso; David M Lyerly; William A Petri; Eric R Houpt
Journal:  Vaccine       Date:  2010-11-21       Impact factor: 3.641

Review 6.  Crosstalk at the initial encounter: interplay between host defense and ameba survival strategies.

Authors:  Xiaoti Guo; Eric Houpt; William A Petri
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

7.  CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils.

Authors:  Catherine P A Ivory; Kathy Keller; Kris Chadee
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 8.  Enteric infections, diarrhea, and their impact on function and development.

Authors:  William A Petri; Mark Miller; Henry J Binder; Myron M Levine; Rebecca Dillingham; Richard L Guerrant
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by gamma interferon.

Authors:  Xiaoti Guo; Lisa Barroso; Steven M Becker; David M Lyerly; Thomas S Vedvick; Steven G Reed; William A Petri; Eric R Houpt
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 10.  Amebic colitis: new insights into pathogenesis and treatment.

Authors:  Tracy E Bercu; William A Petri; Jr W Behm
Journal:  Curr Gastroenterol Rep       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.